language Türkçe
Article 2022 · 7 citations

Efficacy of combination therapy with biofeedback and dapoxetine in lifelong premature ejaculation treatment: a prospective randomized study

Yilmaz, Ali Haydar, Cinislioglu, Ahmet Emre, Demirdogen, Saban Oguz, Yilmazel, Fatih Kursat, Sam, Emre, Karabulut, Ibrahim, Koc, Mahmut, Ozbey, Isa

Abstract

Purpose Premature ejaculation (PE) is a common sexual dysfunction that significantly affects the quality of life of the patient and their partner. We aimed to compare the efficacy and safety of the combination therapy with biofeedback-guided pelvic floor exercise therapy (BFT) and dapoxetine 30 mg. Methods Sixty-five patients diagnosed with lifelong PE were included in the study. Patients were divided into three groups as BFT, dapoxetine 30 mg and a combination of BFT and dapoxetine 30 mg. The patients were compared with the intravaginal ejaculatory latency time (IELT) pre-treatment and post-treatment 1st and 3rd months. Results The mean IELTs of the patients in Group 1 were 40 s in pre-treatment, 115 s at the end of the 4th week and 140 s at the end of the 12th week. The IELT values of the patients in Group 2 were 40 s in pre-treatment, 145 s in the 4th week and 170 s in the 12th week. The IELT values were calculated in Group 3 as 42.5 s in pre-treatment, 185 s in the 4th week and 205 s in the 12th week When the IELT was statistically compared between the groups at 1st and 3rd months, the duration in the combination group was found to increase significantly (p < 0.001). Conclusion Combination therapy with BFT and dapoxetine 30 mg in lifelong PE treatment is a good alternative with a low side effect profile and acceptable continuous efficiency.

Keywords
Biofeedback Dapoxetine Premature Ejaculation Pelvik floor INTEGRATED ANALYSIS DEFINITION REHABILITATION EPIDEMIOLOGY
WoS Categories
Urology & Nephrology
Sustainable Development Goals
Citation
Journal
INTERNATIONAL UROLOGY AND NEPHROLOGY
Year
2022
Volume
54
Issue
11
Pages
2813-2818
ISSN
0301-1623
eISSN
1573-2584
DOI
10.1007/s11255-022-03338-7
WoS UID
WOS:000838533200002
Open via DOI